CABALETTA BIO, INC. Operating Cash Flow
CABALETTA BIO, INC. (CABA) reported Operating Cash Flow of -$84.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$41.51M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$42.56M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$35.34M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$34.51M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$131.08M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$88.22M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$53.55M.
- CABALETTA BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$46.38M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$41.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$84.08M 10-Q · filed 2026-08-13 | -$119.42M derived: sum of 3 quarters · filed 2026-08-13 | -$153.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$42.56M 10-Q · filed 2026-05-14 | -$77.90M derived: sum of 2 quarters · filed 2026-05-14 | -$112.41M derived: sum of 3 quarters · filed 2026-05-14 | -$142.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$35.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$69.85M derived: sum of 2 quarters · filed 2026-03-23 | -$100.28M derived: sum of 3 quarters · filed 2026-08-13 | -$131.08M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$34.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$64.94M derived: sum of 2 quarters · filed 2026-08-13 | -$95.74M 10-Q · filed 2025-11-10 | -$118.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$30.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$61.23M 10-Q · filed 2026-08-13 | -$84.35M derived: sum of 3 quarters · filed 2026-08-13 | -$104.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$30.80M 10-Q · filed 2026-05-14 | -$53.92M derived: sum of 2 quarters · filed 2026-05-14 | -$74.25M derived: sum of 3 quarters · filed 2026-05-14 | -$95.04M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$23.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$43.45M derived: sum of 2 quarters · filed 2026-03-23 | -$64.23M derived: sum of 3 quarters · filed 2026-03-23 | -$88.22M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$20.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$41.11M derived: sum of 2 quarters · filed 2025-11-10 | -$65.10M 10-Q · filed 2025-11-10 | -$81.55M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$20.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$44.78M 10-Q · filed 2025-08-07 | -$61.23M derived: sum of 3 quarters · filed 2025-08-07 | -$73.83M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$23.99M 10-Q · filed 2025-05-15 | -$40.44M derived: sum of 2 quarters · filed 2025-05-15 | -$53.04M derived: sum of 3 quarters · filed 2025-05-15 | -$64.93M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$29.05M derived: sum of 2 quarters · filed 2025-03-31 | -$40.94M derived: sum of 3 quarters · filed 2025-03-31 | -$53.55M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$12.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$24.49M derived: sum of 2 quarters · filed 2024-11-14 | -$37.10M 10-Q · filed 2024-11-14 | -$49.23M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$11.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$24.50M 10-Q · filed 2024-08-08 | -$36.63M derived: sum of 3 quarters · filed 2024-08-08 | -$46.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$12.61M 10-Q · filed 2024-05-15 | -$24.74M derived: sum of 2 quarters · filed 2024-05-15 | -$34.65M derived: sum of 3 quarters · filed 2024-05-15 | -$46.18M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$12.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$22.05M derived: sum of 2 quarters · filed 2024-03-21 | -$33.57M derived: sum of 3 quarters · filed 2024-03-21 | -$46.38M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$9.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$21.44M derived: sum of 2 quarters · filed 2023-11-09 | -$34.25M 10-Q · filed 2023-11-09 | -$44.76M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$11.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$24.34M 10-Q · filed 2023-08-10 | -$34.85M derived: sum of 3 quarters · filed 2023-08-10 | -$43.19M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$12.81M 10-Q · filed 2023-05-11 | -$23.32M derived: sum of 2 quarters · filed 2023-05-11 | -$31.67M derived: sum of 3 quarters · filed 2023-05-11 | -$38.25M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$18.86M derived: sum of 2 quarters · filed 2023-03-16 | -$25.44M derived: sum of 3 quarters · filed 2023-03-16 | -$34.11M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$8.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$14.92M derived: sum of 2 quarters · filed 2022-11-10 | -$23.59M 10-Q · filed 2022-11-10 | -$32.77M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$6.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$15.25M 10-Q · filed 2022-08-11 | -$24.42M derived: sum of 3 quarters · filed 2022-08-11 | -$29.45M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$8.67M 10-Q · filed 2022-05-12 | -$17.84M derived: sum of 2 quarters · filed 2022-05-12 | -$22.87M derived: sum of 3 quarters · filed 2022-05-12 | -$30.51M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$9.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$14.20M derived: sum of 2 quarters · filed 2022-03-17 | -$21.84M derived: sum of 3 quarters · filed 2022-03-17 | -$26.77M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$5.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$12.67M derived: sum of 2 quarters · filed 2021-11-01 | -$17.60M 10-Q · filed 2021-11-01 | -$25.48M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | -$7.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$12.57M 10-Q · filed 2021-08-05 | -$20.46M derived: sum of 3 quarters · filed 2021-08-05 | -$22.53M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$4.93M 10-Q · filed 2021-05-03 | -$12.81M derived: sum of 2 quarters · filed 2021-05-03 | -$14.89M derived: sum of 3 quarters · filed 2021-05-03 | -$18.71M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | -$7.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$9.96M derived: sum of 2 quarters · filed 2021-03-16 | -$13.78M derived: sum of 3 quarters · filed 2021-03-16 | -$16.05M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$5.90M derived: sum of 2 quarters · filed 2020-11-10 | -$8.16M 10-Q · filed 2020-11-10 | -$10.07M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$3.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$6.09M 10-Q · filed 2020-08-06 | -$7.99M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$2.27M 10-Q · filed 2020-05-12 | -$4.17M derived: sum of 2 quarters · filed 2020-05-12 | ||
| 2018-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$4.66M 10-K · filed 2020-03-30 | ||
| 2018-09-30 | -$2.75M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |